Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.62/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.62), versus ($1.52) reported last year.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Nvidia and Broadcom earnings: TD Cowen says earnings won’t settle big questions
• Home Depot beats estimates, reaffirms fiscal 2026 guidance